查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1887664

全球即時血脂檢測市場

POC Lipid Testing
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球即時血脂檢測市場預計2030年將達到3.271億美元

全球即時血脂檢測市場規模在2024年估計為2.709億美元，預計到2030年將達到3.271億美元，在分析期（2024-2030年）內複合年成長率（CAGR）為3.2%。本報告分析的細分市場之一－高血脂症應用領域，預計複合年成長率為3.0%，到分析期末將達到9,700萬美元。高三酸甘油脂血症應用領域預計在分析期內複合年成長率為4.2%。

美國市場規模估計為7,040萬美元，而中國市場預計將以5.5%的複合年成長率成長。

預計到2024年，美國即時血脂檢測市場規模將達7,040萬美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到7,050萬美元，在2024年至2030年的分析期間內，複合年成長率（CAGR）為5.5%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為1.0%和2.4%。在歐洲，德國的複合年成長率預計約為1.5%。

全球即時血脂檢測市場—主要趨勢與促進因素摘要

即時健康洞察：即時血脂檢測的作用

照護現場血脂檢測（POC​​）是指在患者就診時直接測量血脂水平，無需送往中心實驗室即可即時獲得結果。這些檢測通常測量關鍵的血脂指標，例如總膽固醇、高密度脂蛋白膽固醇（HDL）、低密度脂蛋白膽固醇（LDL）和三酸甘油酯，這些指標對於評估心血管健康至關重要。 POC血脂檢測設備通常使用少量指尖血，將其塗抹在試紙或試劑盒上。然後使用攜帶式設備，透過比色法或生物感測器等方法分析血液樣本。快速的檢測結果使醫護人員能夠立即做出臨床決策，從而改善病患管理，並有助於早期療育血脂異常症和其他脂質相關疾病。

如何在臨床環境中應用即時血脂檢測

在臨床實踐中，床邊血脂檢測在常規健康檢查和慢性病管理中都發揮著重要作用。基層醫療醫生在常規體檢中利用這些檢測來監測患者的血脂水平，從而早期發現高血脂症和其他心血管危險因子。對於已知血脂異常症的患者，床邊檢測提供了一種便捷的方法來追蹤治療反應並根據需要調整藥物。在急診情況下，快速血脂檢測有助於對急性冠狀動脈症候群和其他心血管事件的患者進行風險分層。此外，在檢測設施有限的偏遠和資源匱乏地區，床邊血脂檢測是確保患者獲得必要診斷服務的重要工具。床邊血脂檢測的即時和便利性使其成為現代醫學中不可或缺的工具，尤其是在需要快速做出臨床決策的情況下。

目前即時血脂檢測技術的發展趨勢是什麼？

即時血脂檢測（POC​​）技術正不斷發展，其驅動力在於對更高準確性、更便捷的操作以及與更廣泛醫療保健系統整合的需求。一個顯著的趨勢是檢測設備的微型化和便攜化。這些設備變得越來越小巧、更容易使用，以便於在各種醫療環境中應用。生物感測器技術的進步提高了這些設備的靈敏度和特異性，確保了更可靠的檢測結果。與數位健康平台的整合也是一個重要的趨勢，它能夠將檢測結果自動上傳到電子健康記錄（EHR），從而實現遠端監測和遠端醫療應用。此外，人們越來越關注開發能夠同時評估多種健康參數的多分析物即時檢測設備，從而更全面地了解患者的心血管健康狀況。這些創新使即時血脂檢測更加便利、高效和資訊豐富，有助於改善患者照護和管理。

哪些因素正在推動即時血脂檢測市場的成長？

即時血脂檢測市場成長受多種因素驅動，反映出市場對快速可靠診斷工具的需求日益成長。心血管疾病盛行率上升以及全球對預防醫學的重視是關鍵促進因素，因為早期發現和管理血脂異常症對於降低心血管風險至關重要。即時檢測設備的技術進步，例如更高的準確性、便攜性和與數位健康系統的整合，正在促進其在各種醫療機構中的應用。遠端醫療和遠端患者監護的擴展，尤其是在應對新冠疫情期間，也推動了對即時血脂檢測的需求，因為它們支持持續的患者照護，無需頻繁的門診就診。此外，人們對個人化醫療的日益關注也推動了即時檢測的應用，以便根據即時血脂水平評估提供個人化的治療方案。這些因素共同推動了即時血脂檢測市場的強勁成長，凸顯了其在現代醫療保健和慢性病管理中的關鍵作用。

部分：

依應用（高血脂症、高三酸甘油脂血症、遺傳性高膽固醇症、高脂蛋白血症、坦齊爾氏症、其他應用）

受訪公司範例

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Abaxis, Inc.
  • Accutech LLC
  • Alere, Inc.
  • Biochemical Systems International Srl
  • Bio-Rad Laboratories, Inc.
  • Eurotrol BV
  • F. Hoffmann-La Roche AG
  • General Life Biotechnology Co., Ltd.
  • Helena Laboratories Corporation
  • Nova Biomedical Corporation

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具，改變您分析市場和競爭情報的方式。

Market Glass, Inc. 並沒有採用查詢LLM 或產業專用的SLM 的典型方法，而是建立了一個由世界各地領域專家精心策劃的內容庫，其中包括影片文字稿、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

在最新發布的報告中，Market Glass, Inc. 將關稅對地理市場的影響納入考量，並根據公司總部所在地、製造地以及進出口（成品和OEM產品）情況，預測企業競爭地位的變化。這種複雜多變的市場現實會從多個方面影響競爭對手，包括增加銷貨成本、降低盈利和重組供應鏈，同時也會影響微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 亞太其他地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP14040

Global POC Lipid Testing Market to Reach US$327.1 Million by 2030

The global market for POC Lipid Testing estimated at US$270.9 Million in the year 2024, is expected to reach US$327.1 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Hyperlipidemia Application, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$97.0 Million by the end of the analysis period. Growth in the Hypertriglyceridemia Application segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$70.4 Million While China is Forecast to Grow at 5.5% CAGR

The POC Lipid Testing market in the U.S. is estimated at US$70.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$70.5 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global POC Lipid Testing Market - Key Trends and Drivers Summarized

Instant Health Insights: The Role of POC Lipid Testing

Point-of-care (POC) lipid testing refers to the process of measuring lipid levels directly at the site of patient care, providing immediate results without the need for centralized laboratory facilities. This testing typically measures key lipid parameters, including total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides, which are critical for assessing cardiovascular health. POC lipid testing devices often use small blood samples obtained through a finger prick. The blood is applied to a test strip or cassette, which is then analyzed by a portable device using methods such as colorimetric assays or biosensors. The rapid turnaround of results allows healthcare providers to make prompt clinical decisions, enhancing patient management and facilitating early intervention in cases of dyslipidemia and other lipid-related disorders.

How Is POC Lipid Testing Utilized in Clinical Practice?

In clinical practice, POC lipid testing plays a crucial role in both routine health assessments and the management of chronic conditions. Primary care physicians use these tests during regular check-ups to monitor patients' lipid levels, enabling the early detection of hyperlipidemia and other cardiovascular risk factors. For patients with known lipid disorders, POC testing provides a convenient way to track treatment efficacy and adjust medications as needed. In emergency settings, rapid lipid testing can aid in the risk stratification of patients presenting with acute coronary syndromes or other cardiovascular events. Furthermore, POC lipid testing is invaluable in remote and resource-limited settings where access to laboratory facilities may be restricted, ensuring that patients still receive essential diagnostic services. The immediacy and convenience of POC lipid testing make it an indispensable tool in modern healthcare, particularly in scenarios requiring swift clinical decisions.

What Are the Current Trends in POC Lipid Testing Technology?

The technology behind POC lipid testing is continually advancing, driven by the need for greater accuracy, ease of use, and integration with broader healthcare systems. One notable trend is the miniaturization and portability of testing devices, which are becoming increasingly compact and user-friendly, facilitating their use in various healthcare environments. Advances in biosensor technology are enhancing the sensitivity and specificity of these devices, ensuring more reliable results. Integration with digital health platforms is another significant trend, allowing for the automatic upload of test results to electronic health records (EHRs) and enabling remote monitoring and telemedicine applications. Additionally, there is growing interest in developing multi-analyte POC devices that can assess multiple health parameters simultaneously, providing a more comprehensive overview of a patient’s cardiovascular health. These innovations are making POC lipid testing more accessible, efficient, and informative, improving overall patient care and management.

What Factors Are Driving the Growth in the POC Lipid Testing Market?

The growth in the POC lipid testing market is driven by several factors, reflecting the increasing demand for rapid and reliable diagnostic tools. The rising prevalence of cardiovascular diseases and the global emphasis on preventive healthcare are significant drivers, as early detection and management of lipid disorders are critical for reducing cardiovascular risk. Technological advancements in POC testing devices, including improved accuracy, portability, and integration with digital health systems, are enhancing their adoption across various healthcare settings. The expanding use of telemedicine and remote patient monitoring, especially in response to the COVID-19 pandemic, is also boosting demand for POC lipid testing, as it supports ongoing patient care without the need for frequent in-person visits. Additionally, the growing focus on personalized medicine is encouraging the use of POC testing to provide tailored treatment plans based on real-time lipid level assessments. These factors collectively ensure robust growth in the POC lipid testing market, underscoring its vital role in modern healthcare and chronic disease management.

SCOPE OF STUDY:

The report analyzes the POC Lipid Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier disease, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Abaxis, Inc.
  • Accutech LLC
  • Alere, Inc.
  • Biochemical Systems International Srl
  • Bio-Rad Laboratories, Inc.
  • Eurotrol B.V.
  • F. Hoffmann-La Roche AG
  • General Life Biotechnology Co., Ltd.
  • Helena Laboratories Corporation
  • Nova Biomedical Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • POC Lipid Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Global Economic Update
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Cardiovascular Diseases Propels Market Growth
    • Advances in Point-of-Care Diagnostic Technologies Drives Adoption
    • Increasing Focus on Preventive Healthcare Expands Market Opportunities
    • Growth in Home-Based and Remote Testing Strengthens Business Case for POC Lipid Testing
    • Development of Rapid and Accurate Lipid Testing Kits Spurs Market Expansion
    • Expansion of Telemedicine and Digital Health Platforms Generates Demand
    • Increasing Awareness and Screening Programs Accelerates Market Growth
    • Enhanced Convenience and Accessibility of Modern Testing Solutions Sustains Market Demand
    • Technological Innovations in Biosensors and Microfluidics Strengthens Market Position
    • Development of Cost-Effective and Portable Testing Devices Generates Market Opportunities
    • Growth in Health and Wellness Programs Propels Market Growth
    • Increasing Demand for Comprehensive Lipid Profiling and Monitoring Sustains Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for POC Lipid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Hyperlipidemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Hyperlipidemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Hyperlipidemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Hypertriglyceridemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Hypertriglyceridemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Hypertriglyceridemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Familial Hypercholesterolemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Familial Hypercholesterolemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Familial Hypercholesterolemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Hyperlipoproteinemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Hyperlipoproteinemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Hyperlipoproteinemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Tangier Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Tangier Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Tangier Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World POC Lipid Testing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Japan 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: China Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: China 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for POC Lipid Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Europe 15-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Europe 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: France Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: France 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Germany 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Italy 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: UK 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 53: Spain Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Spain Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Spain 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Russia Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Russia 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 59: Rest of Europe Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Rest of Europe Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Rest of Europe 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for POC Lipid Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Asia-Pacific 15-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Asia-Pacific 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 68: Australia Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Australia Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Australia 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 71: India Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: India Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: India 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 74: South Korea Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: South Korea Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: South Korea 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 77: Rest of Asia-Pacific Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Asia-Pacific Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Rest of Asia-Pacific 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for POC Lipid Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Latin America 15-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Latin America 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 86: Argentina Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Argentina Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Argentina 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 89: Brazil Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Brazil Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Brazil 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 92: Mexico Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Mexico Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Mexico 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 95: Rest of Latin America Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Latin America Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Latin America 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for POC Lipid Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Middle East 15-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Middle East 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 104: Iran Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Iran Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Iran 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 107: Israel Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Israel Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Israel 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 110: Saudi Arabia Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Saudi Arabia Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Saudi Arabia 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 113: UAE Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UAE Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UAE 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 116: Rest of Middle East Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Middle East Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Middle East 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 119: Africa Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Africa Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Africa 15-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION